Loading...
•
Sep 30, 2020
Protagonist Q3 2020 Earnings Report
Reported third quarter financial results and provided a corporate update.
Key Takeaways
Protagonist Therapeutics reported its financial results for the third quarter ended September 30, 2020. The company's clinical assets PTG-300, PN-943 and PTG-200, are progressing in Phase 2 clinical proof-of-concept studies. Two additional oral interleukin-23 receptor antagonists, PN-235 and PN-232, were selected for advancement into clinical development in collaboration with Janssen.
PTG-300, PN-943 and PTG-200 continue to make progress in Phase 2 clinical proof-of-concept studies.
Updated clinical data from Phase 2 study of PTG-300 in patients with polycythemia vera will be shared in December.
Ongoing Phase 2 clinical programs with PN-943 in patients with ulcerative colitis, and PTG-200 in patients with Crohn’s disease are moving forward.
Two additional oral interleukin-23 receptor antagonists, PN-235 and PN-232, were selected for advancement into clinical development in collaboration with Janssen.
Forward Guidance
The press release contains forward-looking statements regarding the potential of product candidates to improve standards of care, the ability to fund operations into future periods, and expectations regarding the timing of the initiation of clinical trials.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...